Rezaei Negar, Maghsodlu Mahtab, Sheidaei Ali, Kafiabad Sedigheh Amini, Gohari Kimiya, Zadsar Maryam, Delavari Farnaz, Sharifi Zohreh, Yoosefi Moein, Farzadfar Farshad, Asadi-Lari Mohsen
Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Public Health. 2021 Sep;50(9):1854-1862. doi: 10.18502/ijph.v50i9.7058.
High risk blood transfusions can cause a lot of financial and psychological burden to the community. The prevalence of Hepatitis B is useful for evaluating the blood products' safety and donor selection methods. We aimed to predict the prevalence of hepatitis B in Iranian blood donors from 2000-2016.
Positive cases of hepatitis B from 2006 to 2014 were collected from Iranian Blood Transfusion Organization. This database was classified according to the age, provinces, and type of donation. Data was not existed in all subnational levels and all years, therefore, for predicting the hepatitis B prevalence, two separate, Spatio-temporal and mixed model (GLMM) were developed.
At the national level, the hepatitis B prevalence declined from 0.69 (0.51 to 0.90) in 2000 to 0.27 (0.21 to 0.33) in 2016. In first-time, regular, and repeated donors, this prevalence declined from 2.31 (1.74 to 2.31), 0.26 (0.19 to 0.34), and 0.51 (0.38 to 0.68) in 2000 to 0.87 (0.69 to 1.09), 0.09 (0.07 to 0.12), and 0.19 (0.14 to 0.24) in 2016. At the provincial level, the highest and lowest prevalence in 2016 was observed in North Khorasan and Gilan. With increasing age, the average prevalence of hepatitis B, increased.
Prevalence of hepatitis B in Iranian blood donors has been reduced significantly over 17 years, but still new cases of hepatitis B are reported. By precise monitoring the donor selection process and implementing more sensitive laboratory screening, we can reduce the risk of new infectious agents.
高风险输血会给社会带来巨大的经济和心理负担。乙型肝炎的流行情况有助于评估血液制品的安全性和献血者选择方法。我们旨在预测2000年至2016年伊朗献血者中乙型肝炎的流行情况。
从伊朗输血组织收集2006年至2014年乙型肝炎阳性病例。该数据库根据年龄、省份和献血类型进行分类。并非所有次国家级层面和所有年份都有数据,因此,为了预测乙型肝炎的流行情况,开发了两个单独的时空模型和混合模型(广义线性混合模型)。
在国家层面,乙型肝炎的流行率从2000年的0.69(0.51至0.90)降至2016年的0.27(0.21至0.33)。在首次献血者、定期献血者和重复献血者中,这一流行率从2000年的2.31(1.74至2.31)、0.26(0.19至0.34)和0.51(0.38至0.68)降至2016年的0.87(0.69至1.09)、0.09(0.07至0.12)和0.19(0.14至0.24)。在省级层面,2016年最高和最低流行率分别出现在北呼罗珊省和吉兰省。随着年龄的增长,乙型肝炎的平均流行率有所上升。
伊朗献血者中乙型肝炎的流行率在17年里显著下降,但仍有新的乙型肝炎病例报告。通过精确监测献血者选择过程并实施更敏感的实验室筛查,我们可以降低新传染源的风险。